Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapeutic products for cancer and chronic degenerative diseases (e.g., spinal cord injury, heart failure) based on telomerase and human embryonic stem cell (hESC) technologies. The company operates as a single segment focused on discovery and development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|
| Total Revenues | $198 | $1,892 | $1,805 |
| Operating Expenses | $15,656 | $33,299 | $34,973 |
| Loss from Operations | $(15,458) | $(31,407) | $(33,168) |
| Net Loss | $(13,564) | $(27,238) | $(12,818) |
| Net Loss per Share (Basic/Diluted) | $(0.17) | $(0.35) | $(0.23) |
| Cash and Cash Equivalents | $127,080 (as of June 30, 2008) | ||
| Marketable Securities | |||
| Total Current Assets | $192,917 | ||
| Total Current Liabilities | $8,579 | ||
| Accumulated Deficit | $(472,110) |
Material Changes vs. Prior Period
- Revenues: Total revenues for the six months ended June 30, 2008, increased slightly to $1.89 million from $1.81 million in the prior year. This was driven by a $1.5 million milestone payment from Exeter Life Sciences related to FDA risk assessment on cloned animals, offset by a significant decrease in collaborative agreement revenues ($166k vs. $597k) due to changes in the consolidation of the TA Therapeutics joint venture.
- Operating Expenses: Total operating expenses decreased to $33.3 million from $35.0 million. Research and Development (R&D) expenses declined to $25.2 million from $27.3 million, primarily due to reduced drug product purchases ($2.4 million) and consulting fees ($2.2 million), partially offset by increased personnel costs and clinical trial expenses.
- Net Loss: Net loss for the six months increased to $27.2 million from $12.8 million. This increase is largely attributable to a non-cash unrealized gain on derivatives of $901,000 in 2008 compared to a gain of $14.8 million in 2007, as well as decreased interest income due to lower rates and balances.
- Liquidity: Cash and cash equivalents decreased by approximately $18.9 million during the six-month period, primarily due to cash used in operating activities ($20.9 million).
Outlook, Risks, and Management Commentary
- Clinical Holds: The FDA placed a clinical hold on the company's Investigational New Drug (IND) application for GRNOPC1 (hESC-derived oligodendrocyte progenitor cells) for the treatment of acute spinal cord injury. Clinical trials cannot commence without FDA authorization.
- Capital Needs: Management estimates existing capital resources will fund operations through at least December 2009. However, the company anticipates continued losses and will require substantial additional capital to fund future operations and clinical trials. Future funding may come from strategic collaborations, equity financings, or debt.
- R&D Focus: The company is advancing two major platforms:
- Oncology: Phase I trials for telomerase inhibitor GRN163L (various cancers) and Phase II trials for telomerase vaccine GRNVAC1 (acute myelogenous leukemia).
- hESC Therapies: Developing cell therapies for spinal cord injury, heart failure, and diabetes.
- Key Risks:
- Uncertainty of regulatory approvals and potential delays in clinical trials.
- Dependence on third-party collaborators and joint ventures.
- Intellectual property challenges, including patent oppositions in Europe regarding telomerase vaccines and hESC technologies.
- Need for additional financing which may result in dilution.
Investor Verification Checklist
- Clinical Hold Status: Verify the current status of the FDA clinical hold on the GRNOPC1 spinal cord injury program and any conditions for lifting it.
- Cash Runway: Confirm the sufficiency of the $186.7 million in cash and marketable securities to fund operations through the projected December 2009 date, considering potential increases in clinical trial costs.
- Derivative Liability: Review the valuation assumptions (Level 3 inputs) for the $701,000 derivative liability and the impact of future stock price volatility on the income statement.
- Intellectual Property: Monitor the outcome of pending patent oppositions in Europe regarding telomerase vaccines (Pharmexa) and hESC patents (WARF reexamination appeals).
- Revenue Recognition: Assess the sustainability of revenue streams, noting the heavy reliance on milestone payments and the reduction in collaborative revenue from the TA Therapeutics joint venture.